Publication | Open Access

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Cardiovascular ToxicityC-reactive Protein ReductionCardiovascular DiseaseCardiovascular PharmacologyEvent ReductionPharmacotherapyPreventive CardiologySecondary AnalysisMedicineAtherosclerosisMyocardial Infarction